Wednesday Feb 04, 2026
Ep. 19 - A year of impact: MiniMed™ 780G highlights
Kick off the New Year with us as we celebrate the MiniMed™ 780G system research that defined 2025! From compelling discoveries to data that propelled technology forward, get ready for a dynamic recap that inspires and sets the stage for an exciting year ahead!
Product usage represented may not be approved or cleared in all markets.
Due to inherent data limitations, caution is advised when attempting to extrapolate these results to new patients. There could be significant differences.
1. Bhargava A., et al. Diabetes Technol & Ther. 2025;27(5): 366-375. http://dx.doi.org/10.1089/dia.2024.0586
2. Nally LM, et al. Safety and Glycemic Outcomes of the MiniMed™ 780G System with a Disposable All-in-One Sensor. Diabetes Technology and Therapeutics. 18 August 2025 https://doi.org/10.1177/15209156251368928
3. Vigersky, R et al. MiniMed™ 780G system users achieve consensus glycemic goals regardless of size of carbohydrate entry. American Diabetes Association 85th Scientific Sessions | Chicago, IL | June 20th – 23rd, 2025
4. McVean, J et al. Days without user-initiated boluses: real-world performance of the MiniMed™ 780G system. [A2481] American Diabetes Association 85th Scientific Sessions | Chicago, IL | June 20th – 23rd, 2025
5. Thijs I, et al. JDST. 2025. Mar 1212:19322968251318373. doi: 10.1177/19322968251318373. Epub ahead of print. PMID: 40071717; PMCID: PMC11954135 6. McVean J, et al. Achieved and Sustained Glycemic Outcomes with Reduction in Burden: Three-year real-world follow up of the MiniMed 780G system. EASD 61st Annual Meeting, Vienna, Austria 15-19 September 2025
The MiniMed™ 780G system is intended for the continuous delivery of basal insulin at selectable rates and the administration of insulin boluses at selectable rates for the management of type 1 diabetes mellitus in persons 7 years of age and older, and of type 2 diabetes mellitus in persons 18 years of age and older requiring insulin. The system is also intended to continuously monitor glucose values in the fluid under the skin.
The MiniMed™ 780G System includes SmartGuard™ technology, which can be programmed to automatically adjust insulin delivery based on the continuous glucose monitoring (CGM) sensor glucose values and can suspend delivery of insulin when the sensor glucose (SG) value falls below or is predicted to fall below predefined threshold values. The system is intended for use with connected sensors, including the Simplera Sync™ and Guardian™ 4 sensors and integrated continuous glucose monitors, including the Instinct sensor, each of which has different wear-time, form factor, insertion site, and other distinguishing characteristics that relate to sensor performance. Consult the appropriate sensor user guide when using the system. Discuss treatment decisions with your HCP.
WARNING: Do not use the SmartGuard™ feature for people who require less than 8 units or more than 250 units of total daily insulin per day. A total daily dose of at least 8 units, but no more than 250 units, is required to operate in the SmartGuard™ feature.
WARNING: Do not use the MiniMed™ 780G system until appropriate training has been received from a healthcare professional. Training is essential to ensure the safe use of the MiniMed™ 780G system.
WARNING: Do not use SG values to make treatment decisions, including delivering a bolus, while the pump is in Manual Mode. When the SmartGuard™ feature is active and you are no longer in Manual Mode, the pump uses an SG value, when available, to calculate a bolus amount. However, if your symptoms do not match the SG value, use a blood glucose (BG) meter to confirm the SG value. Failure to confirm glucose levels when your symptoms do not match the SG value can result in the infusion of too much or too little insulin, which may cause hypoglycemia or hyperglycemia.
Pump therapy is not recommended for people whose vision or hearing does not allow for the recognition of pump signals, alerts, or alarms. The safety of the MiniMed™ 780G system has not been studied in pregnant women or in persons using other anti-hyperglycemic therapies that do not include insulin. For complete details of the system, including accessories and additional important safety information concerning indications, contraindications, warnings and precautions associated with the system and its components, please consult https://www.medtronicdiabetes.com/important-safety-information#minimed-780g and the appropriate user guide at https://www.medtronicdiabetes.com/download-library